We do not conduct early-stage discovery in isolation. We identify promising science through collaboration with world-class universities, research institutions, and commercial partners. Those relationships are central to how we build and scale our portfolio.
The University of Manchester is where the science underpinning SkinBioTherapeutics‘ oral ingredient development originated.
Research conducted at the University provided the foundational discoveries that inform our approach to the gut-skin axis and microbiome-derived actives.
Winclove Probiotics is a specialist probiotic manufacturer based in the Netherlands and the manufacturing partner behind AxisBiotix.
Winclove brings proprietary Probioact® technology to the partnership. This technology is designed to protect bacterial strains through the manufacturing process and gastrointestinal transit, maintaining viability and potency through to delivery. This is a critical capability for an oral microbiome product where strain survival directly affects efficacy.
SkinBioTherapeutics worked in partnership with Croda, one of the world’s leading speciality chemical companies, on Zenakine™: the world’s first neurocosmetic ingredient, which is based on SkinBiotix intellectual property.
This partnership combines SkinBioTherapeutics’ microbiome science expertise with Croda’s formulation capability and commercial scale.
For more information on Zenakine, please visit Croda’s product page.